NuVasive Stock Forecast, Price & News

NuVasive (NASDAQ:NUVA) Frequently Asked Questions

Is NuVasive a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NuVasive stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View analyst ratings for NuVasive or view top-rated stocks.

How has NuVasive's stock been impacted by COVID-19?

NuVasive's stock was trading at $49.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NUVA shares have increased by 14.5% and is now trading at $56.59.
View which stocks have been most impacted by COVID-19.

When is NuVasive's next earnings date?

NuVasive is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for NuVasive.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings results on Tuesday, November, 9th. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.54 by $0.22. The medical device company earned $270.84 million during the quarter, compared to analysts' expectations of $291.32 million. NuVasive had a negative net margin of 2.27% and a positive trailing twelve-month return on equity of 11.40%. During the same quarter last year, the company earned $0.54 earnings per share.
View NuVasive's earnings history.

How will NuVasive's stock buyback program work?

NuVasive announced that its Board of Directors has authorized a share repurchase plan on Tuesday, November 9th 2021, which allows the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy up to 3.5% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's management believes its stock is undervalued.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive updated its FY 2021 earnings guidance on Tuesday, December, 7th. The company provided EPS guidance of $1.730-$1.830 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.230. The company issued revenue guidance of $1.13 billion-$1.14 billion, compared to the consensus revenue estimate of $1.19 billion.

What price target have analysts set for NUVA?

11 equities research analysts have issued twelve-month price targets for NuVasive's stock. Their forecasts range from $54.00 to $83.00. On average, they anticipate NuVasive's share price to reach $65.67 in the next twelve months. This suggests a possible upside of 16.0% from the stock's current price.
View analysts' price targets for NuVasive or view top-rated stocks among Wall Street analysts.

Who are NuVasive's key executives?

NuVasive's management team includes the following people:

• J. Christopher Barry, Chief Executive Officer & Director (LinkedIn Profile)
• Dale Wolf, Senior Vice President-Global Operations
• Matthew K. Harbaugh, Chief Financial Officer & Executive Vice President
• Kyle Malone, VP-Clinical, Medical & Regulatory Affairs
• Ryan Donahoe, Chief Technology Officer

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive CEO Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among NuVasive's employees.

Who are some of NuVasive's key competitors?

Some companies that are related to NuVasive include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX).
View all of NUVA's competitors.

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Frontier Capital Management Co. LLC (1.14%), Scout Investments Inc. (1.03%), Retirement Systems of Alabama (0.13%), Profit Investment Management LLC (0.09%), Clear Street Markets LLC (0.02%) and State of Alaska Department of Revenue (0.01%). Company insiders that own NuVasive stock include James Christopher Barry, Lucas Vitale, Massimo Calafiore and Matthew Link.
View institutional ownership trends for NuVasive.

Which institutional investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Wolff Wiese Magana LLC, State of Alaska Department of Revenue, and IFP Advisors Inc. Company insiders that have sold NuVasive company stock in the last year include James Christopher Barry, Lucas Vitale, and Massimo Calafiore.
View insider buying and selling activity for NuVasive or view top insider-selling stocks.

Which institutional investors are buying NuVasive stock?

NUVA stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Clear Street Markets LLC, Profit Investment Management LLC, Retirement Systems of Alabama, Crossmark Global Holdings Inc., and Exchange Traded Concepts LLC.
View insider buying and selling activity for NuVasive or or view top insider-buying stocks.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $56.59.

How much money does NuVasive make?

NuVasive has a market capitalization of $2.93 billion and generates $1.05 billion in revenue each year. The medical device company earns $-37.15 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does NuVasive have?

NuVasive employs 2,700 workers across the globe.

Does NuVasive have any subsidiaries?

The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, and SafePassage.

When was NuVasive founded?

NuVasive was founded in 1997.

What is NuVasive's official website?

The official website for NuVasive is www.nuvasive.com.

Where are NuVasive's headquarters?

NuVasive is headquartered at 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at (858) 909-1800, via email at [email protected], or via fax at 800-475-9134.